Highly concentrated therapeutic areas, fierce competition for patient enrollment in clinical trials and low efficiency in initiating studies are just some of the main issues unveiled in a new annual report on clinical studies in China.
On 10 November, the Center for Drug Evaluation (CDE), the new drug review wing of the National Medical Products Administration, released its first such report breaking out data for for clinical studies, based on data